Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

Vanda Pharmaceuticals Inc. Form 4 September 24, 2008

September 2	24, 2008										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB APPROVAL			
	Check this box if no longer subject to Section 16. Form 4 or								OMB Number:	3235-0287	
if no lor subject Section									Expires: Estimated a burden hour response	•	
obligation may cor <i>See</i> Inst 1(b).	ntinue. Section 17	(a) of the P	ublic U	Itility Hol		pany	Act of	1935 or Section			
Print or Type	Responses)										
1. Name and TANG KE	5	2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (Middle)	3. Date of Earliest Transaction (Check								
4401 EAST		(Month/Day/Year)					Director Owner Officer (give title Other (specify below) below)				
		-					6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person				
SAN DIEC	GO, CA 92121							_X_ Form filed by M Person			
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative S	Securi	ties Acqu	ired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	curity (Month/Day/Year) Execution Date, if T astr. 3) any C			3. Transactio Code (Instr. 8)	4. Securitie on Dispose (Instr. 3, 4	d of (E and 5) (A)))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	09/22/2008			Code V P	Amount 100,000	or (D) A	Price \$ 0.9988	(Instr. 3 and 4) 4,939,058	I <u>(1)</u>	By LP <u>(1)</u>	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Code	5. ofNumber of Derivativ Securitie Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D (Month/Day, ve ss 1	Expiration Date (Month/Day/Year) e		e and nt of lying ties 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V			Expiration Date		Amount or Number of Shares		

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

Reporting Owners

Reporting Owner Name / Ad	dress	Relationsh					
	Director	10% Owner	Officer	Other			
TANG KEVIN C 4401 EASTGATE MALL SAN DIEGO, CA 92121		Х					
TANG CAPITAL MANAGEM 4401 EASTGATE MALL SAN DIEGO, CA 92121	ENT LLC	Х					
TANG CAPITAL PARTNERS 4401 EASTGATE MALL SAN DIEGO, CA 92121	LP	Х					
Signatures							
/s/ Kevin C. Tang					09/24/2008		
	Date						
/s/ Kevin C. Tang, Managing M	09/24/2008						
		Date					
/s/ Kevin C. Tang, as Managin Partner	09/24/2008						
	**Signature of Reporting F	Person			Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities are held by Tang Capital Partners, LP. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the (1) general partner of Tang Capital Partners, LP. Mr. Tang disclaims beneficial ownership of the securities except to the extent of his

pecuniary interest therein. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.